Also trades as: PROF (NASDAQ) · $vol 1M
PRN.TO TSX
Profound Medical Corp.
1W: -4.8%
1M: +3.0%
3M: +2.9%
YTD: +8.9%
1Y: +33.2%
3Y: -28.3%
5Y: -61.3%
C$9.42 ($6.84)
+0.18 (+1.95%)
Weekly Expected Move ±8.3%
C$8
C$9
C$9
C$10
C$11
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Smart Money Score
No convergence signal
Key Statistics
Market CapC$279.6M ($203.1M)
52W Range5.23-12.4
Volume5,931
Avg Volume18,521
Beta0.50
Dividend—
Analyst Ratings
Company Info
CEOArun Swarup Menawat
Employees142
SectorHealthcare
IndustryMedical - Devices
IPO Date2018-07-10
Websiteprofoundmedical.com
2400 Skymark Avenue
Mississauga, ON L4W 5K5
CA
Mississauga, ON L4W 5K5
CA
647 476 1350
About Profound Medical Corp.
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
-logo-1200x675.PNG?v=20210211152252){kind=logo}
Recent Insider Trades
No insider trades found